Shoji Okinaga
- Pulmonary and Respiratory Medicine top 1%
- Molecular Biology top 5%
- Oncology top 2%
- Immunology top 5%
- Physiology top 5%
- Co-authors
- Shigeki ShibaharaHidetada SasakiMutsuo YamayaKiyohisa SekizawaNorihiro YamadaKatsutoshi NakayamaNorma P. GerardTakashi Ohrui
- Topics
- Lung Cancer Treatments and Mutations (10 papers)Heme Oxygenase-1 and Carbon Monoxide (10 papers)Lung Cancer Research Studies (9 papers)
- Journals
- Proceedings of the National Academy of SciencesJournal of Biological ChemistryJournal of Clinical Oncology
- Partner nations
- JapanSouth KoreaUnited States
In The Last Decade
Shoji Okinaga
47 papers receiving 3.7k citations
Hit Papers
Peers
Comparison fields: 5 of 129
- Pulmonary and Respiratory Medicine 1.6k
- Molecular Biology 1.5k
- Oncology 1.1k
- Immunology 642
- Physiology 535
Countries citing papers authored by Shoji Okinaga
This map shows the geographic impact of Shoji Okinaga's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shoji Okinaga with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shoji Okinaga more than expected).
Fields of papers citing papers by Shoji Okinaga
This network shows the impact of papers produced by Shoji Okinaga. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shoji Okinaga. The network helps show where Shoji Okinaga may publish in the future.
Co-authorship network of co-authors of Shoji Okinaga
This figure shows the co-authorship network connecting the top 25 collaborators of Shoji Okinaga. A scholar is included among the top collaborators of Shoji Okinaga based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shoji Okinaga. Shoji Okinaga is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 31 | |
| 3 | 5 | |
| 4 | 23 | |
| 5 | 34 | |
| 6 | Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)breakdown → | 427 |
| 7 | 2 | |
| 8 | 369 | |
| 9 | 156 | |
| 10 | Nitroglycerin treatment may increase response to docetaxel and carboplatin regimen via inhibitions of hypoxia-inducible factor-1 pathway and P-glycoprotein in patients with lung adenocarcinoma | 9 |
| 11 | 56 | |
| 12 | 117 | |
| 13 | 1 | |
| 14 | 471 | |
| 15 | 26 | |
| 16 | 9 | |
| 17 | 231 | |
| 18 | 5 | |
| 19 | 41 | |
| 20 | 168 |
About Shoji Okinaga
Shoji Okinaga is a scholar working on Critical Care and Intensive Care Medicine, Endocrine and Autonomic Systems and Emergency Medical Services, having authored 49 papers that have together received 3.8k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (10 papers), Heme Oxygenase-1 and Carbon Monoxide (10 papers) and Lung Cancer Research Studies (9 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (1.6k citations), Oncology (1.1k citations) and Critical Care and Intensive Care Medicine (178 citations). Shoji Okinaga has collaborated with scholars based in Japan, South Korea and United States. Frequent co-authors include Shigeki Shibahara, Hidetada Sasaki, Mutsuo Yamaya, Kiyohisa Sekizawa, Norihiro Yamada, Katsutoshi Nakayama, Norma P. Gerard, Takashi Ohrui, Koichi Hagiwara and Makoto Maemondo. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.